Corey Walker, MD
Rheumatology · Logan, UTNPI 1295707677
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Amgen at 38.6% of the total. Reporting peaked in 2020 at $1,612 and has fallen 56.6% since, to $700 in 2025.
Across 48 payments — averaging $96.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Boehringer Ingelheim$1K
- AbbVie$425
- AstraZeneca$301
- E.r. Squibb & Sons, L.L.C.$296
- Johnson & Johnson$219
- plus $378 from 7 others
What the payments were for
- Consulting fees$1,92542%
- Travel & lodging$1,17926%
- Food & beverage$1,28428%
- Education$2345%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 8 | $1,785 |
| Boehringer Ingelheim | 3 | $1,219 |
| AbbVie | 1 | $425 |
| AstraZeneca | 5 | $301 |
| E.r. Squibb & Sons, L.L.C. | 19 | $296 |
| Johnson & Johnson | 3 | $219 |
| Alphatec Spine, Inc | 2 | $202 |
| Lilly USA, LLC | 1 | $52 |
| Globus Medical | 1 | $44 |
| Pfizer | 2 | $32 |
| Genentech USA, Inc. | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,623 in reported general payments places this provider in the 70th percentile of 52 rheumatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 75 | $428,322 |
| Humira(Cf) PenAdalimumab | 43 | $411,390 |
| Enbrel SureclickEtanercept | 45 | $331,913 |
| Taltz AutoinjectorIxekizumab | 27 | $188,221 |
| Orencia ClickjectAbatacept | 28 | $169,987 |
| RinvoqUpadacitinib | 21 | $132,803 |
| Humira PenAdalimumab | 17 | $112,634 |
| KevzaraSarilumab | 25 | $107,999 |
| SimponiGolimumab | 16 | $99,794 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 13 | $88,175 |
| Humira(Cf)Adalimumab | 12 | $79,385 |
| Actemra ActpenTocilizumab | 11 | $52,005 |
| OlumiantBaricitinib | 11 | $32,997 |
| MethotrexateMethotrexate Sodium | 743 | $18,925 |
| Hydroxychloroquine Sulfate | 427 | $14,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $425 | $212,18933 claims |
| Johnson & JohnsonSimponi | $219 | $99,79416 claims |
| Lilly USA, LLCOlumiant | $52 | $32,99711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 52 rheumatology providers in Utah.
Other rheumatology in Logan
- Adam MeierLogan$480
- Catherine BakewellSalt Lake City$1M
- Jessica WalshSlc$162K
- Shruti SanghviVineyard$63K
- Curry KoeningSalt Lake City$59K
- Carmen GotaSt. George$56K
- Seung Yoon LeeMurray$22K
- Matthew CallSpringville$17K
- Wenshu YuProvo$17K
- Michael DarleyProvo$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.